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Summary
BACKGROUND AND AIMS: Direct-acting antiviral agents
have revolutionised hepatitis C treatment. In 2014, the
Swiss Hepatitis Strategy was developed to eliminate he-
patitis C virus (HCV) infection and the associated liver-re-
lated morbidity and mortality by 2030. Though numerous
national studies and assessments have identified a rela-
tively low prevalence rate of 0.7% in the country, little has
been done to identify the epidemiology of HCV on the re-
gional, or micro, level. This study aimed to identify scenar-
ios to achieve the objectives of Swiss Hepatitis Strategy by
2030 in eastern, western and northern regions in Switzer-
land.
METHODS: Three Excel-based Markov disease burden
models, based on hospital- and region-specific data, were
developed to forecast the current and future prevalence
of HCV infection by fibrosis stage and liver disease stage
to 2030. Two scenarios were developed to evaluate the
disease burden in St Gallen, Geneva and Zurich: a Base
2016 scenario, representing the current standard of care
in each canton, and a second, potential scenario to
achieve the Swiss Hepatitis Strategy goals.
RESULTS: In 2015, the estimated viraemic prevalence in
St Gallen was 0.5% (0.5–0.6%) corresponding to 2800
(2600–3100) cases. In Geneva and Zurich, the estimated
prevalence was slightly higher, with an estimated 0.7%
(0.6–0.7%) viraemic prevalence, or 3300 (3000–3600)
cases in Geneva and 0.7% (0.7–0.8%) viremic preva-
lence, or 10,800 (9900–11,900) infectionsin Zurich. In or-
der to achieve the Swiss Hepatitis Strategy goals of a 30%
reduction in new infections, total viraemic infections, liver
transplants, and hepatocellular carcinoma cases by 2020
and a 90% reduction by 2030, all regions will need to in-
crease the annual number of treated and diagnosed pa-
tients up to 2030. In St Gallen, an up-front investment to
treat 430 patients annually by 2020 would be necessary, to
achieve the 2020 goals. After 2020, treatment could be re-
duced to ~150 patients annually until 2030. The number of
patients diagnosed, however, would need to be sustained
at 130 annually after 2020. In Geneva, 235 patients need
to be treated, with 140 diagnosed annually between 2019
and 2030 to achieve both 2020 and 2030 goals. In Zurich,
850 patients will need to be treated annually in 2019 and
2020 and the number of diagnosed will need to expand to
350 individuals annually by 2022.
CONCLUSIONS: Intensified screening for chronic hepati-
tis C and increased access to direct-acting antivirals are
necessary to meet the Swiss hepatitis strategy elimination
goals over the next 12 years.
Keywords: hepatitis C virus, liver cirrhosis, hepatocellular
carcinoma, Switzerland
Introduction
In 2016, the World Health Organization (WHO) identified
viral hepatitis as a pandemic becuase of its associated sub-
stantial public health and economic burdens [1]. Affecting
communities and health systems across the world, viral he-
patitis was responsible for more deaths than the human im-
munodeficiency virus (HIV) and tuberculosis in the previ-
ous year [1]. Hepatitis C virus (HCV) infection is a leading
cause of liver cirrhosis, decompensated cirrhosis and he-
patocellular carcinoma (HCC), often requiring expensive
therapies and procedures such as liver transplants, or re-
sulting in premature death. Chronic hepatitis C (CHC) af-
fects more than 71 million people worldwide and was re-
sponsible for approximately 400,000 deaths in 2015 [1,
2]. Though HCV inflicts undue health and economic dam-
age on countries, the opportunity for public health strate-
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gies to tackle the disease burden has been revived. Given
the development of newer, more efficacious treatment reg-
imens such as direct-acting antivirals (DAAs), strategies
can now be created that address the elimination, rather than
the management, of HCV globally.
In high-income countries such as Switzerland, with a rel-
atively low prevalence and expanded access to DAA ther-
apy, to cure and eliminate HCV is possible. Given this
situation, a multi-stakeholder network launched the Swiss
Hepatitis Strategy [3], with the goal of reducing morbidity
and mortality caused by viral hepatitis C and eliminate it
by 2030. The strategy outlined a reduction of the number
of new infections, of chronic HCV infections, and of liver
transplants and HCC cases caused by HCV. Though a re-
cent situational analysis estimated an overall anti-HCV
prevalence of 0.7% and, after adjustment, reported
36,000–43,000 viraemic cases (estimated prevalence
0.49%) in 2015 [4] (roughly three times that of HIV [4]),
only a minority of patients has been cured thus far. Since
1995, approximately 4000 people have died in connection
with HCV in Switzerland, about five times as many deaths
as from HIV or hepatitis B virus (HBV) [4].
Previous modelling work has evaluated the forecasted im-
pact of increased access to more efficacious therapies
[5–7]. Considering more than 40 countries throughout Eu-
rope and Asia, these studies showed that, although signif-
icant reductions in disease burden are plausible, strategies
to improve diagnosis and treatment capacity are needed in
order to do so [5–7]. More recent modelling studies have
quantified the estimated diagnostic and treatment expan-
sion necessary to achieve the Global Health Sector Strat-
egy goals for elimination of viral hepatitis by 2030 [8, 9].
These studies highlighted impediments on the pathway to
care and analysed the trade-offs between segments of the
patient population to be targeted – considerations countries
must account for in order to achieve elimination. Particu-
larly, although increased treatment coverage and sustained
virological response (SVR) in later stage liver disease have
the greatest short-term impact on reducing morbidity and
mortality, treatment of early stage fibrosis (F0–F1) is nec-
essary to achieve reductions in total viraemic infections
and prevent ongoing transmission [9]. These reports are
helpful in the initial planning and development of national
HCV policies, but modelling of elimination strategies
amongst specific populations or sub-regions is limited. De-
velopment of possible microelimination scenarios break-
ing down national elimination goals into individual popu-
lation segments [10] enables policy makers to understand
current disease landscapes on a hospital-based or regional
level.
In late 2017, Switzerland took a first step towards elim-
ination by lifting treatment restrictions to allow ≥F0 pa-
tients to receive treatment. Alongside this change was an
increase in the number of patients starting treatment, which
exceeded the 7% threshold that puts Switzerland on track
for elimination [11]. However, high treatment levels can be
difficult to sustain, especially if there is an insufficient pool
of patients diagnosed and linked to care. Thus, there is a
growing need to identify HCV management strategies in
the cantons throughout Switzerland.
This study aimed to identify scenarios that could achieve
the Swiss Hepatitis Strategy by 2030 at the regional level.
In this analysis, we modelled the current epidemiological
landscape of HCV and identified the increases in diagnosis
and treatment ratesthat might be necessary to achieve the
strategy goals in eastern (region of St Gallen), western (re-
gion of Geneva) and northern (region of Zurich) Switzer-
land.
Materials and methods
Three regions in Switzerland were included in this analy-
sis: St Gallen, a region in eastern Switzerland containing
the cantons of Appenzell Innerrhoden, Appenzell Ausser-
rhoden and St Gallen. It has approximately 570,000 in-
habitants (at the end of 2016) [12], representing almost
10% of the Swiss population. Geneva, a region in southern
Switzerland including the canton of Geneva, is the second
most populous city in the country, with a resident popula-
tion (at the end of 2016) of approximately 489,500 [12].
Zurich, a region in northern Switzerland including the can-
ton of Zurich, is the largest city in the country, with a pop-
ulation of 1.5 million inhabitants [12].
Hepatitis C disease burden model
An Excel-based Markov disease burden model was de-
veloped to forecast the current and future prevalence of
HCV infection stratified by fibrosis stage, and of associat-
ed liver-related morbidity and mortality. A comprehensive
description of this model has been published previously
[2, 13–15]. A disease progression model was construct-
ed to estimate the HCV-infected population by liver dis-
ease stage, from 1950 to 2030. The model estimates the
annual number of acute infections that progress to chronic
HCV infection, after accounting for spontaneous clearance
of the virus. The progression of these new cases by age and
sex was followed, with adjustments for mortality and cure.
Three models were populated with published data or expert
feedback and calibrated with canton-specific assumptions
to forecast the future burden of HCV by sequelae through
to 2030. The three models were based on canton-specific
data and outcome values were fitted to these historical pa-
rameters. A full description of the model can be found in
appendices 1 and 2.
Data collection – St Gallen
The St Gallen model was seeded with data gathered from
the Cantonal Hospital of St Gallen (KSSG). Electronic
medical records from 1 January 2004 and 31 December
2016 of all patients with a positive anti-HCV screening
test (acute or chronic HCV infection) presenting at the hos-
pital were analysed retrospectively. Patient characteristics
such as age, year of hepatitis C diagnosis, diagnosis of
acute hepatitis C, stage of liver fibrosis (liver elastogra-
phy and/or liver biopsies were used to define the individ-
ual fibrosis score according to METAVIR [16]), treatment
regimen and outcome (SVR12), co-infections (HIV, HBV,
hepatitis A virus [HAV]), HCC and liver transplantation
due to HCV were assessed. This information was used as
input data (treatment numbers, treatment outcomes, geno-
type distribution, age distribution, HCC and liver trans-
plantation due to HCV, actual stage of liver fibrosis) for the
St Gallen model (table 1). The study was approved by the
ethical committee in eastern Switzerland, with the project-
ID 2017-00693.
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Table 1: Inputs by cantonal model.
St Gallen Source Geneva Source Zurich Source
Viraemic prevalence
rate (2015)
0.49%
(0.45–0.55%)
[4] 0.65%
(0.59–0.71%)
Calculated 0.73%
(0.68–0.81%)
Calculated
Total diagnosed vi-
raemic
2,025
(2013*)
[17] 2095
(2015*)
[17] 6470
(2015*)
[17]
Annual newly diag-
nosed
85
(2013*)
[17] 96
(2015*)
[17] 184
(2015*)
[17]
Annual treated (2016) 113 [18] 191 [18] 515 [18]
HCV liver transplants 1
(2015*)
KSSG 6
(2016*)
University Hospital,
Geneva
3
(2016*)
University Hospital,
Zurich
HCV = hepatitis C virus; KSSG = Kantonsspital St. Gallen / Cantonal Hospital St Gallen * Denotes year of estimate
Data collection – Geneva
Genotype distribution and liver transplant data from the
University Hospital of Geneva were used. Liver cancer da-
ta by histology, including HCC, were collected from 1990
to 2013 from the Geneva Liver Tumour Registry (table 2).
Ethical approval was not necessary in Geneva as only ag-
gregated totals were used.
Data collection – Zurich
The genotype distribution was based on Switzerland cohort
data, which gave an estimate that approximately 29% of
cases had genotype 3 and 26% genotypes 1a and 1b [19,
20]. Liver transplant data from the University Hospital
Zurich were used. Zurich liver cancer data from
1988–2014 was collected (table 2). Ethical approval was
not necessary in Zurich as only aggregated totals were
used.
Table 2: Annual number of reported liver cancer cases.
Year Cases in Geneva Cases in Zurich
1988 73
1989 61
1990 28 73
1991 36 67
1992 39 74
1993 36 62
1994 25 66
1995 35 73
1996 38 85
1997 43 74
1998 36 81
1999 40 77
2000 35 82
2001 49 94
2002 47 97
2003 64 85
2004 46 98
2005 62 85
2006 40 79
2007 47 101
2008 46 86
2009 55 99
2010 47 148
2011 49 109
2012 62 132
2013 69 121
2014 132
Prevalence estimate
Regional HCV prevalence by canton was not available and
had to be estimated from available data – national HCV
prevalence, reported liver cancer cases by canton, and re-
ported HCV diagnoses (after adjusting for treatment and
mortality) by canton [4, 17]. Expert consensus was used to
check for consistency of the prevalence estimates across all
three regions. Attempts to use the reported numbers of all
and newly diagnosed cases by canton to estimate regional
prevalence was not successful as they were influenced by
the number of centres treating HCV and the level of testing
in each region.
The anti-HCV prevalence in St Gallen was estimated to
be the same as the published viraemic HCV prevalence
in Switzerland: 0.49% (95% confidence interval [CI]
0.45–0.54) [4]. Geneva and Zurich have more diverse im-
migrant populations, which made extrapolation from na-
tional data more difficult. The reported liver cancer cases
in each region were used to back-calculate the total number
of HCV infections required to result in the reported cancer
cases. The prevalence estimates generated (table 1) were
higher than the national prevalence, as expected.
The total number of HCV infections was estimated by mul-
tiplying the regional prevalence and the population of the
cantons in each region. For St Gallen, the 2015 population
of the cantons Appenzell Innerrhoden, Appenzell Ausser-
rhoden and St Gallen was used [17]. Notification data, pro-
vided by the Swiss Federal Office of Public Health, was
used to form the age and gender distribution of the model,
yearly number of new HCV infections and diagnosed cas-
es.
Historically diagnosed patients
The total number of HCV diagnosed cases in the cantons
Appenzell Innerrhoden, Appenzell Ausserrhoden and St
Gallen, Geneva and Zurich (1990–2016) and the yearly
number of new HCV infections were based on the cases re-
ported to the Swiss Federal Office of Public Health [17],
after accounting for mortality and cure. The reported
chronic cases were stratified into 1-year age cohorts and
were aged forward each year, taking into account reported
background mortality in the individual age cohorts, as well
as reported treatment and cure rates based on rates of SVR.
Historically treated patients
The annual number of treated patients in St Gallen was col-
lected in the study described above. All specialised care of
HCV patients in the cantons of St Gallen and Appenzell is
centralised in the cantonal hospital. The annual number of
treated patients for Geneva and Zurich was scaled from na-
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tional estimates using IMS Health data (2004–2015) [18].
Geneva and Zurich account for 10% and 30% of total
Swiss HCV infections, respectively. It was assumed that
they accounted for the same proportion of the HCV treated
population. Since all patients, regardless of fibrosis score,
were eligible for treatment from 2018, and Geneva and
Zurich are the two largest cantons in Switzerland, it was
believed that a larger proportion of patients linked to care
would be captured in these regions.
Scenarios
Two scenarios were developed to evaluate the disease bur-
den in St Gallen, Geneva and Zurich: Base 2016 and Swiss
Hepatitis Strategy. The inputs by scenario can be found in
tables 3a and 3b.
The Base 2016 scenario assumes that the current standard
of care will continue in the individual cantons up to 2030.
For St Gallen, treatment was restricted to those with liver
fibrosis grade ≥F2 and aged 18 to 84 years to represent
the treatment restrictions across Switzerland up to the end
of 2017. This was expanded to ≥F0 in 2018 to represent
the updated treatment guidelines in Switzerland, which ex-
panded eligibility to all patients regardless of fibrosis stage
at the end of 2017. SVR was set to an average of 96%
to represent patients receiving DAAs. Under this scenario,
approximately 110 patients are treated annually and 90 pa-
tients newly diagnosed each year up to 2030.
Similar fibrosis and age restrictions and SVR rates were
applied to the Base 2016 scenario for Geneva and Zurich.
In 2016, those ≥F2 and aged over 18 years were eligible for
treatment; however, beginning in 2018, this was relaxed to
≥F0. The SVR rates by genotype that were applied in the
St Gallen model were also incorporated into the models
for Geneva and Zurich. An estimated 190 patients and 520
patients were treated in Geneva and Zurich, respectively,
in 2016. This number was expected to stay constant over
time; 140 and 180 patients were diagnosed each year in
Geneva and Zurich, respectively, up to 2030.
Table 3a: Inputs by scenario for St Gallen, Geneva, and Zurich 2015–2030: Base 2016.
2015 2016 2017 2018-2030
St Gallen
Treated 107 113 113 113
Newly diagnosed 85 85 85 85
Fibrosis stage ≥F2 ≥F2 ≥F2 ≥F0
Treated age 20–85+ 20–85+ 20–85+ 20–85+
SVR 96% 96% 96% 96%
Geneva
Treated 232 191 191 191
Newly diagnosed 96 96 96 96
Fibrosis stage ≥F2 ≥F2 ≥F2 ≥F0
Treated age 20–85+ 20–85+ 20–85+ 20–85+
SVR* 97% 97% 97% 97%
Zurich
Treated 626 515 515 515
Newly diagnosed 184 184 184 184
Fibrosis stage ≥F2 ≥F2 ≥F2 ≥F0
Treated age 20–85+ 20–85+ 20–85+ 20–85+
SVR* 97% 97% 97% 97%
SVR = sustained viral response
* Although SVR by genotype was the same across all regions, the average SVR was different because of the different genotype distribution in the three cantons.
Table 3b: Inputs by scenario for St Gallen, Geneva, and Zurich 2015–2030: Swiss Hepatitis Strategy*.
2018 2019 2020 2022 2025
St Gallen
Treated 250 350 430 160 150
Newly diagnosed 100 100 130 130 130
Fibrosis stage ≥F0 ≥F0 ≥F0 ≥F0 ≥F0
Treated age 20–85+ 20–85+ 20–85+ 20–85+ 20–85+
SVR 97% 97% 97% 97% 97%
Geneva
Treated 230 240 240 240 240
Newly diagnosed 140 140 140 140 140
Fibrosis stage ≥F0 ≥F0 ≥F0 ≥F0 ≥F0
Treated age 20–85+ 20–85+ 20–85+ 20–85+ 20–85+
SVR 97% 97% 97% 97% 97%
Zurich
Treated 750 850 850 800 800
Newly diagnosed 200 250 300 350 350
Fibrosis stage ≥F0 ≥F0 ≥F0 ≥F0 ≥F0
Treated age 20–85+ 20–85+ 20–85+ 20–85+ 20–85+
SVR 97% 97% 97% 97% 97%
SVR = sustained viral response * The inputs are the same as the base 2016 scenario for years 2015-2017. Numbers are rounded values.
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Under the Swiss Hepatitis Strategy, diagnosis and treat-
ment was increased in order to achieve a 30% reduction in
new infections, total viraemic infections, liver transplants
and HCC cases by 2020 and a further 90% reduction by
2030. The outcomes by scenario were then compared.
Results
Epidemiology of hepatitis C in St Gallen, Geneva and
Zurich
In 2015, the estimated viraemic prevalence in St Gallen
was 0.5% (0.5–0.6%), corresponding to 2800
(2600–3,100) chronic HCV cases. In Geneva and Zurich,
the estimated prevalence was slightly higher, with an es-
timated 0.7% (0.6–0.7%) viraemic prevalence, or 3300
(3000–3600) cases in Geneva and 0.7% (0.7–0.8%) vi-
raemic prevalence, or 10,800 (9900–11,900) infections in
Zurich in the same year. Of these, approximately 70% of
the viraemic population was found to be between the ages
of 30 and 64. The distribution by age and sex can be seen
in figures 1–6. In St Gallen, the median age was 52 years,
whereas in Geneva it was slightly older at 54 years. Ac-
cording to hospital-based data, in both cantons there were
more male patients, who represented more than 60% of
cases (65% in St Gallen vs 61% in Geneva). More than
half of all patients had ever been treated in both St Gallen
(52.2%) and Geneva (58.5%). Of these, 83% were cured
in St Gallen, whereas in Geneva almost three-quarters of
patients were cured. This hospital-specific data could not
be provided for Zurich at the time of publication. The can-
ton-specific cascade of care for 2017 is represented in fig-
ures 7–9. The distribution of viraemic cases under the Base
2016 scenario is summarised in figures 10–12.
Figure 1: Age and sex distribution of hepatitis C cases in the can-
ton of St Gallen in 2015.
Figure 2: Age and sex distribution of hepatitis C cases in the can-
ton of Geneva in 2015.
Base 2016 scenario
The liver-related morbidity and mortality by scenario and
canton can be seen in figures 13–15. Given the number of
patients treated with DAA therapy, decreases in liver-re-
lated morbidity and total viraemic infections are expected
over the next 15 years. Under the Base 2016 scenario, the
St Gallen model forecasts a reduction of liver-related death
by about 10% in 2020 and by 35% in 2030, whereas liv-
er cancer due to HCV would decline by more than 10% in
2020 and close to 40% in 2030. The model also estimates a
Figure 3: Age and sex distribution of hepatitis C cases in the can-
tons of St Gallen, Geneva and Zurich in 2015.
Figure 4: Distribution of hepatitis C cases by five year age cohort
in the canton of St Gallen in 2015.
Figure 5: Distribution of hepatitis C cases by five year age cohort
in the canton of Geneva in 2015.
Figure 6: Distribution of hepatitis C cases by five year age cohort
in the canton of Zurich in 2015.
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reduction of chronic infections by 20% in 2020 and 70% in
2030. Decompensated cirrhosis cases are also forecasted to
decline, by 10% in 2020 and by 35% by 2030. By retaining
Figure 7: The hepatitis C cascade of care, including total viremic
infections, diagnosed, treated and cured, in the canton of St Gallen
for 2017.
Figure 8: The hepatitis C cascade of care, including total viremic
infections, diagnosed, treated and cured, in the canton of Geneva
for 2017.
Figure 9: The hepatitis C cascade of care, including total viremic
infections, diagnosed, treated and cured, in the canton of Zurich
for 2017.
Figure 10: Distribution of viremic infections by disease stage in
the canton of S. Gallen, from 1950–2030 under the Base 2016
scenario.
a rate of 95 newly diagnosed patients per year, 90% of all
infected patients would be detected in 2030.
In Geneva, the model estimates a more rapid decline in liv-
er-related morbidity and mortality. There would be a re-
duction of liver-related death by 35% in 2020 and 85% in
2030, whereas liver cancer due to HCV would be reduced
by 30% in 2020 and 80% in 2030. There is also a fore-
casted decline of chronic infections by 30% in 2020 and
approximately 90% in 2030. Decompensated cirrhosis cas-
es are forecasted to decline by 45% by 2020 and 90% by
2030. By retaining a rate of 96 newly diagnosed patients
per year, almost all infected patients would be detected in
2030.
In Zurich, an even greater impact is seen on the estimated
HCV prevalence and associated liver-related morbidity
and mortality. There would be a reduction of liver-related
death by 15% in 2020 and 60% in 2030, whereas liver can-
cer due to HCV would be reduced by 15% in 2020 and
60% in 2030. There is also a forecasted decline of chronic
infections of 20% in 2020 and 60% in 2030. Decompensat-
ed cirrhosis cases were estimated to drop by 20% by 2020
and 70% by 2030. By retaining a rate of 180 newly diag-
nosed patients per year, almost all infected patients would
be detected in 2030.
Swiss Hepatitis Strategy
In order to achieve these goals for St Gallen, fibrosis re-
strictions were relaxed to ≥F0 in 2018 in order to increase
the pool of patients eligible for treatment. Treated age and
SVR remained the same as in the Base 2016 scenario
(18–84 years, 97%); however, the number of patients treat-
ed was increased to 350 in 2020 (in 2016 only 107 patients
were treated at the Cantonal Hospital St Gallen). Further-
more, the number of new diagnoses increased from 90 pa-
Figure 11: Distribution of viremic infections by disease stage in the
canton of Geneva from 1950–2030 under the Base 2016 scenario.
Figure 12: Distribution of viremic infections by disease stage in
the canton of Zurich from 1950–2030 under the Base 2016 sce-
nario.
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tients annually to 130 from 2020. With these increases dur-
ing the following 10 years, a modelled reduction of total
chronicly infected patients by 40% in 2020 and 100% in
2030 can be achieved. More, the model shows a reduction
in HCC due to HCV of 30% in 2020 and 95% in 2030;
liver related deaths could be reduced by 30% in 2020 and
100% in 2030. Lastly, decompensated cirrhosis cases are
forecasted to decline by 30% in 2020 and 100% in 2030. In
total, approximately 2700 chronic hepatitis C patients have
to be treated during 2016–2030 in eastern Switzerland to
achieve the Swiss Hepatitis Strategy goals.
In Geneva, similar increases in treatment and newly diag-
nosed cases were necessary. The number of treated patients
was increased to 2015 treatment levels (235 patients treat-
ed annually) in 2018 and maintained up to 2030. The num-
ber diagnosed will need to increase to 140 individuals an-
nually from 2018. Treatment was also extended to those
≥F0 in 2018. SVR remained constant.
With 240 treated patients per year during the following 10
years, a modelled reduction of all chronicly infected pa-
tients by 35% in 2020 and 100% in 2030 can be achieved.
The estimated number of HCC cases due to HCV is fore-
casted to decline by of 40% in 2020 and 100% in 2030,
whereas decompensated cirrhosis cases are estimated to
decrease by 60% by 2020 and 100% by 2030. Liver related
deaths could be reduced by 45% in 2020 and 100% in
2030.
In Zurich, the number of patients that are needed to be
treated will peak at 850 patients annually in 2019 and
2020. This then declines to 800 patients annually up to
2030. The number diagnosed will need to increase to 350
individuals annually by 2022. Treatment was also expand-
ed to those ≥F0 in 2018. SVR remained constant.
Given these increases in diagnosed and treated cases, the
total number of chronicly infected patients, HCC cases due
to HCV, decompensated cirrhosis cases and liver related
deaths will all decrease drastically, by 95% by 2030.
As shown in table 4, achieving the Swiss Hepatitis Strategy
targets in the three cantons will have significant impact
on morbidity and mortality in the HCV-infected popula-
tion. In St Gallen, by 2030 approximately 65 new cases of
HCC and 50 new cases of decompensated cirrhosis could
be averted and 95 lives could be saved. In Geneva, 25 and
20 new cases of HCC and decompensated cirrhosis, re-
spectively, could be averted by 2030. Additionally, 30 lives
could be saved. In Zurich, the largest reduction in morbid-
ity and mortality could be seen. More than 175 new cases
of HCC and more than 140 new cases of decompensated
cirrhosis could be averted over the next 12 years. Two hun-
dred and sixty lives could be saved by implementing this
scenario.
Discussion
Summary of main findings
This analysis presented the epidemiological burden of he-
patitis C in various cantons throughout Switzerland and
identified potential scenarios for achieving the Swiss He-
patitis Strategy goals by 2030. Our study estimated a high-
er prevalence of HCV in Geneva and Zurich than in
Switzerland overall. Similar studies have highlighted this
Table 4: Hepatocellular carcinoma and decompensated cirrhosis cas-
es averted, and lives saved from 2015–2030 under the Swiss Hepatitis
Strategy, by canton.
St Gallen Geneva Zurich
Hepatocellular carcino-
ma cases averted
65 25 180
Decompensated cirrho-
sis cases averted
50 20 140
Lives saved 95 30 260
Values are rounded
Figure 13: Total viraemic infections, liver related morbidity and mortality by scenario for the canton of St Gallen.
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difference in infected cases between urban and rural re-
gions. A study from France, for example, noted an in-
creased risk of HCV infection among Parisians as com-
pared with the overall French population [21]. Thus,
targeted, evidence-based screening and treatment strate-
gies are needed, as the epidemiological burden is quite di-
verse across cantons.
The current standard of care in St Gallen, Geneva and
Zurich is sufficient to reduce the chronic hepatitis popu-
lation and HCV-related impact on liver related morbidity
and mortality. This, however, is based on the assumption
that current trends in numbers of diagnosed and treated pa-
tients will be maintained. If efforts are not in place to sus-
tain such a standard of care, reductions in late stage mor-
bidity and mortality would falter. In Georgia, for example,
which initatied the world’s first programme to eliminate
hepatitis C by 2020, the estimated number of persons start-
ing treatment peaked in September 2016, but has since de-
clined, indicating that interventions to increase access to
HCV testing, care and treatment are needed if the country
is to achieve its national targets [22]. Similar challenges
were faced in Egypt, where additional, outside assistance
Figure 14: Total viraemic infections, liver related morbidity and mortality by scenario for the canton of Geneva.
Figure 15: Total viraemic infections, liver related morbidity and mortality by scenario for the canton of Zurich.
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was needed in order to sustain its formal screening strategy
[23]. The healthcare system in Switzerland has been re-
sponsive to these issues, with treatment access extended to
all patients regardless of fibrosis score in 2017. Although
this is a positive step, identifying available patients and
linking them to treatment still remains a bottleneck in these
regions. Increases in both treatment and diagnosis rates are
necessary if St Gallen, Geneva and Zurich are to achieve
the Swiss Hepatitis Strategy targets set out in 2014. In
Geneva, maintaining the previous standard of care (235
treated patients per year by 2018) would be required to
achieve such targets. However, the number of patients di-
agnosed annually would also need to increase if the strate-
gic goals are to be met. In Zurich, treatment would need
to increase by 100 patients and the annual number of diag-
nosed patients would need to double. A recent Swiss study
analysed the age distribution of HCV cases in the country
in order to develop better screening strategies. It was found
that screening those born between 1951 and 1985 would
capture almost 75% of all infections in Switzerland [24]. St
Gallen, Geneva and Zurich, which diagnose less than 70%
of their viraemic population, could consider such tailored
screening strategies in order to capture enough patients to
treat in order meet the Swiss strategy goals.
Comparison with other research
In 2014, the World Health Organization (WHO) estab-
lished the Global Health Sector Strategy (GHSS) goals for
elimination of hepatitis globally by 2030, like the Swiss
Hepatitis Strategy, [25]. As of 2017, treatment restrictions
were removed across Switzerland, such that all patients
were eligible for treatment regardless of fibrosis score. In
cantons such as St Gallen and Geneva, where almost half
of patients seen in the hospital setting were ≥F2, this poli-
cy shift was necessary if the Swiss Hepatitis Strategy and
WHO Goals are to be achieved. Other countries and mod-
elling efforts have evaluated the possibility of elimination
by 2030 by targeting high-risk populations, such as peo-
ple who inject drugs (PWID). In Iceland, unique in its ge-
ographic isolation and relatively small chronically infected
population (880–1300 people), an HCV transmission mod-
el was used to estimate the treatment and testing scale up
necessary among PWID to achieve the WHO HCV elim-
ination targets [26]. The study evlauted strategies similar
to those used in this cantonal analysis, and also showed
that additional testing and harm reduction efforts are re-
quired [26]. The study also suggested targeted community
based strategies that could be used to achieve local elimi-
nation of HCV [26]. Efforts such as these regional analy-
ses highlight the importance of tailored, context-specific
programmes and could be used by other cities with com-
parable epidemiological landscapes to define what scale
ups in prevention and treatment are required in order to
achieve elimination targets.As long as national strategic
plans for HCV are warranted on a global level, the fea-
sibility, funding, and implementation of such plans must
be considered. Thus, smaller scale policy initiatives target-
ing specific populations or localities are a tangible step to-
wards achieving global elimination of HCV. This analysis
sets forth pragmatic and defined strategies, in three regions
across Switzerland, which could be used as models for
larger intervention programmes or similar analyses across
the country.
Programmatic implications
Though the prospect of achieving the GHSS goals in
Switzerland can be daunting, it is clear from this study
that achieving these goals in subregions is plausible, if cer-
tain programmatic changes are implemented. Increasing
the proportion of diagnosed cases is a key constraint in
these cantons. Screening programmes in the “baby
boomer” population have previously been estimated to be
the most successful in identifying new cases [27] and also
proven to be cost effective [28]. In St Gallen and Geneva,
where the mean age of patients was the early-to-mid fifties,
such screening strategies could be one potential avenue
for identifying patients to diagnose and link to care. These
policies could then be adapted to other cantons throughout
Switzerland or to cities with a comparable age distribution
in the HCV-infected population, in order to meet needs
in specific treatment settings [10]. Similar modelling con-
ducted in Australia has shown the need to improve the cas-
cade of care from infection to treatment and cure and, in
particular, ensure priority populations have access to test-
ing, care and DAA therapy [29]. Such strategies could be
implemented by improving follow up in primary care ser-
vices, such as general practitioner-initiated screening [30,
31].
Although not considered in this analysis, there is also a
need for robust harm reduction programmes to supplement
these screening and treatment strategies. As the majority of
new infections in Europe occur amongst PWID and men
who have sex with men (MSM) and engage in high-risk
behaviour, the potential for reinfection in these cohorts
could partly counteract the benefits achieved by increased
treatment. The prevalence of HCV has been decreasing
amongst PWID in Switzerland [32], as more than 85% of
injection drug users were found to be engaged in harm
reduction programmes [33]. However, in the absence of
these behavioural interventions, the number of secondary
infections would increase regardless of treatment [33]. Ad-
ditionally, two recent studies in Switzerland considered the
impact of increased treatment on the reduction in new in-
fections amongst HIV-positive MSM [34, 35]. It was found
that increased treatment initation reduced HCV incident in-
fections by 50% [35] and that intensive interventions could
boost long-term efforts for prevention of high-risk behav-
iours [34]. Thus, systematic population based screening,
scale up of treatment, and increased access to harm reduc-
tion programmes are necessary for sustained reduction of
new HCV infections and elimination of the disease [35].
Limitations
A number of limitations to the study may affect the fore-
casts of the model. Without a national surveillance pro-
gramme, uncertainty in the prevalence estimates will re-
main. To date, no general population prevalence studies
have been conducted in the regions. However, all estimates
have been presented with 95% uncertainty intervals to cap-
ture such uncertainty in the outcomes. Similarly, though
notification data were used to estimate the total number
of linked-to-care patients in the cantons, underreporting,
especially in high-risk groups, may occur. If this is the
case, then policies would need to capture larger numbers
of diagnosed patients moving forward. Lastly, no treatment
registry exists in Switzerland and thus the true numbers
of treated patients in Geneva and Zurich are unknown.
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As they represent large cities with more prevalent migrant
populations, we assumed a proportional distribution of
treatment in these regions. Further analysis to identify the
number of patients linked to care is warranted.
Conclusion
Elimination of chronic HCV infection in western, eastern,
and northern Switzerland by 2030 is possible, but not with
the current HCV detection or treatment rate. Intensified
HCV screening and increased DAA access are necessary
to meet the Swiss Hepatitis Strategy elimination goals over
the next 15 years.
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Appendix 2
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